Axcella Health Inc. (NASDAQ:AXLA) Short Interest Update

Axcella Health Inc. (NASDAQ:AXLAGet Rating) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 169,200 shares, a decrease of 18.1% from the March 31st total of 206,700 shares. Based on an average daily volume of 102,200 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.8% of the shares of the stock are sold short.

AXLA has been the subject of a number of research reports. SVB Leerink dropped their target price on shares of Axcella Health from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Thursday, March 31st. Zacks Investment Research raised shares of Axcella Health from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a report on Monday, April 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $8.13.

Shares of NASDAQ AXLA opened at $1.75 on Wednesday. The company has a 50 day simple moving average of $2.17 and a 200 day simple moving average of $2.31. Axcella Health has a 1 year low of $1.44 and a 1 year high of $5.90. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 1.14.

Axcella Health (NASDAQ:AXLAGet Rating) last released its earnings results on Wednesday, March 30th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). During the same quarter last year, the business earned ($0.40) EPS. As a group, research analysts expect that Axcella Health will post -1.42 EPS for the current fiscal year.

In other news, major shareholder Des Produits Nestle S. Societe acquired 3,141,361 shares of the business’s stock in a transaction that occurred on Wednesday, March 16th. The stock was acquired at an average price of $1.91 per share, with a total value of $5,999,999.51. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robert Crane acquired 39,267 shares of the business’s stock in a transaction that occurred on Wednesday, March 16th. The shares were purchased at an average cost of $1.91 per share, with a total value of $74,999.97. The disclosure for this purchase can be found here. Insiders have purchased 3,230,366 shares of company stock valued at $6,169,999 in the last ninety days. 6.50% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of Axcella Health by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 140,497 shares of the company’s stock worth $418,000 after buying an additional 3,614 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Axcella Health by 7.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 96,913 shares of the company’s stock worth $202,000 after buying an additional 6,439 shares during the period. Pinnacle Private Wealth LLC grew its position in shares of Axcella Health by 43.9% during the 1st quarter. Pinnacle Private Wealth LLC now owns 29,500 shares of the company’s stock worth $76,000 after buying an additional 9,000 shares during the period. Virtu Financial LLC acquired a new stake in Axcella Health in the 4th quarter valued at $47,000. Finally, Millennium Management LLC grew its position in Axcella Health by 579.6% in the 2nd quarter. Millennium Management LLC now owns 92,688 shares of the company’s stock valued at $372,000 after purchasing an additional 79,049 shares during the period. 61.84% of the stock is owned by institutional investors.

About Axcella Health (Get Rating)

Axcella Health Inc operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients.

See Also

Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.